Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Bushen Sequential Formula (JBSF) is a Traditional Chinese Medicine (TCM) herbal protocol developed to mitigate the adverse effects of adjuvant chemotherapy in patients with colon cancer. The formula is designed based on the TCM principles of 'Jianpi' (strengthening the spleen) and 'Bushen' (tonifying the kidney) to address chemotherapy-induced nausea and vomiting (CINV) and myelosuppression. The 'sequential' nature of the formula typically involves administering specific herbal combinations timed to the phases of the chemotherapy cycle (such as the oxaliplatin and capecitabine/CAPEOX regimen). Clinical research, including a multi-center randomized controlled trial (NCT03716518), focuses on its ability to improve chemotherapy completion rates, reduce treatment toxicity, and extend the time to treatment failure by supporting the patient's gastrointestinal and hematological health during oncology treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianpi Bushen Sequential Formula.